XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko Purchases 4,134 Shares

XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko acquired 4,134 shares of XOMA stock in a transaction on Friday, March 21st. The shares were bought at an average cost of $23.89 per share, with a total value of $98,761.26. Following the completion of the transaction, the executive now owns 10,484 shares of the company’s stock, valued at approximately $250,462.76. This trade represents a 65.10 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Bradley Sitko also recently made the following trade(s):

• On Wednesday, January 8th, Bradley Sitko bought 313 shares of XOMA stock. The shares were bought at an average price of $25.60 per share, with a total value of $8,012.80.
• On Tuesday, December 31st, Bradley Sitko purchased 300 shares of XOMA stock. The stock was bought at an average price of $25.90 per share, for a total transaction of $7,770.00.

XOMA Price Performance

Shares of XOMA stock opened at $20.97 on Friday. The company has a 50-day simple moving average of $23.89 and a two-hundred day simple moving average of $26.95. XOMA Co. has a twelve month low of $19.92 and a twelve month high of $35.00. The stock has a market capitalization of $251.20 million, a price-to-earnings ratio of -6.03 and a beta of 1.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million. Analysts forecast that XOMA Co. will post -1.41 EPS for the current year.

Wall Street Analysts Forecast Growth

XOMA has been the subject of a number of research analyst reports. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a report on Friday, March 21st. HC Wainwright restated a “buy” rating and issued a $104.00 price target on shares of XOMA in a research note on Wednesday, March 19th.

Institutional Trading of XOMA

Large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its stake in XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 800 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 1,183 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 2,009 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of XOMA during the 4th quarter worth approximately $206,000. 95.92% of the stock is owned by institutional investors and hedge funds.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.